What Testing and Evaluation Is Recommended After an Ozempic Gastroparesis Diagnosis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Targeted Legal Risk

If you or a loved one is experiencing persistent nausea, vomiting, or abdominal pain after taking Ozempic, it may be gastroparesis—a condition where the stomach empties too slowly. Understanding the recommended follow-up testing and evaluation is critical for managing this condition. Building on decades of medical research into drug-induced gastrointestinal disorders, this page outlines the key diagnostic steps and monitoring strategies for Ozempic-associated gastroparesis.

Find Out If You Qualify for Compensation →

Ozempic and Gastroparesis: Medical Evidence and Risk Context

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Its pharmacological action slows gastric emptying, a mechanism that can contribute to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has been reported in association with Ozempic use. Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In trials with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal symptoms, which may overlap with or progress to gastroparesis. Mechanistically, GLP-1 receptor agonists like Ozempic inhibit gastric motility and slow gastric emptying via vagal and enteric nervous system pathways. This effect is intended to reduce postprandial glucose excursions but can become pathological, leading to gastroparesis. The timeline between Ozempic exposure and documented harm varies; symptoms often emerge during dose escalation or after prolonged use. In clinical trials, gastrointestinal adverse reactions were most common during the initial weeks of treatment, but persistent symptoms may indicate gastroparesis. Patients who develop severe or persistent nausea, vomiting, or abdominal distension should undergo evaluation for gastroparesis, including gastric emptying studies.

Legal Considerations: Statute of Limitations for Ozempic Claims in Texas

Regarding risk anchors, the adequacy of warnings for Ozempic and gastroparesis is a key consideration. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not specifically list gastroparesis as a contraindication or warning. The label notes that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported, and caution is advised for patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not explicitly warn about the risk of gastroparesis, which may be considered an inadequacy in risk communication. Patients who develop gastroparesis after Ozempic use may argue that the manufacturer failed to provide adequate warnings about this specific adverse effect. Settlement-related considerations for affected patients in Texas involve the statute of limitations, which governs the time frame within which a lawsuit must be filed. In Texas, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For gastroparesis allegedly caused by Ozempic, the clock typically starts when the patient is diagnosed or when symptoms become severe enough to prompt medical evaluation. Given that gastrointestinal symptoms may be initially attributed to other causes, the discovery rule may extend the filing period. Patients should consult with a Texas attorney to determine the applicable deadline based on their specific circumstances. The timeline between Ozempic exposure and documented harm is critical for legal claims. Patients who used Ozempic for months or years before developing gastroparesis must establish a causal link. Medical records documenting the onset of symptoms, diagnostic tests (e.g., gastric emptying studies), and the temporal relationship to Ozempic use are essential. Settlement negotiations may consider the strength of the evidence linking Ozempic to gastroparesis, the severity of the patient's condition, and the adequacy of warnings. Patients with well-documented cases may be eligible for compensation for medical expenses, lost wages, pain and suffering, and other damages. In summary, Ozempic use is associated with gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The prescribing information does not specifically warn about gastroparesis, which may be a basis for legal claims. Texas patients should be aware of the two-year statute of limitations from the date of discovery of their injury. Legal consultation is recommended to evaluate individual cases and ensure timely filing. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Texas?

In Texas, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For gastroparesis allegedly caused by Ozempic, the clock typically starts when the patient is diagnosed or when symptoms become severe enough to prompt medical evaluation. The discovery rule may extend the filing period if symptoms were initially attributed to other causes. Patients should consult a Texas attorney to determine their specific deadline.

Does Ozempic's prescribing information warn about gastroparesis?

The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not specifically list gastroparesis as a contraindication or warning. The label notes serious hypersensitivity reactions but does not explicitly warn about the risk of gastroparesis, which may be considered an inadequacy in risk communication. This could be a basis for legal claims by patients who develop gastroparesis after Ozempic use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.